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Abstract
Background: Timely diagnosis of meningeal carcinomatosis is often difficult even with the assistant of magnetic
resonance imaging examination, cerebrospinal fluid analysis, or both. To the best of our knowledge, gadobutrol-
enhanced MRI has not been reported in the diagnosis of meningeal carcinomatosis. Here we present two cases
where meningeal carcinomatosis was identified on gadobutrol-enhanced magnetic resonance imaging.
Case presentation: We identified two cases of meningeal carcinomatosis who had been diagnosed with malignant
tumors several years ago. Both patients presented with progressive headache and seizures. Gadopentetate
dimeglumine-enhanced magnetic resonance imaging of the brain was performed and did not detect any
abnormality of meninges. Lumbar puncture was performed repeatedly, but cerebrospinal fluid cytology
showed no evidence of malignant cells. Finally the gadobutrol-enhanced magnetic resonance imaging
detected the meningeal metastasis, and supported the diagnosis of meningeal carcinomatosis.
Conclusion: Gadobutrol provides higher lesion conspicuity and enhances lesion detection in meningeal metastasis
compared with gadopentetate dimeglumine. Our observation is a cue to analyze the accuracy in the diagnosis of
meningeal carcinomatosis, and presents a choice that may facilitate early diagnosis.
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Background
Meningeal carcinomatosis (MC) which results from the
multifocal seeding of meninges by malignant cells is di-
agnosed in 1–5 % of patients with malignant tumors [1].
MC is much more frequently observed in patients diag-
nosed with lung and breast cancer, melanoma as well as
lymphoma and leukemia. The clinical presentation of
MC, such as headache and nerve palsy is non-specific,
but the condition deteriorates very quickly. The gold
diagnosis standard is cerebrospinal fluid (CSF) cytology,
and the neuroradiographic examination with gadolinium
magnetic resonance imaging (gdMRI) facilitates the
diagnosis [2]. However timely diagnosis of MC is often
difficult even with the assistant of MRI examination,
CSF analysis, or both. Radiotherapy and chemotherapy
are the main therapeutic approaches, and the supportive
treatment is also very important for symptom relief. The
prognosis for MC is poor and the median survival is
between 4 and 6 weeks [3]. Early diagnosis and interven-
tion help improve quality of life and prevent further
neurological deterioration in MC. To the best of our
knowledge, gadobutrol-enhanced MRI has not been re-
ported in the diagnosis of MC. In this study, we present
two cases of MC detected by gadobutrol-enhanced MRI
and give a choice that may facilitate early diagnosis.
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A 44-year-old female was transferred to our depart-
ment with a 1-month history of headache, nausea and
vomiting. The patient had been diagnosed with cervical
cancer and had undergone radical cervix resection
followed by 6-period chemotherapy 1 year before ad-
mission. Gadopentetate dimeglumine-enhanced MRI of
the brain (Philips Achieva 3.0 T Dual MRI, 0.1 mmol/
kg, immediately after injection) was performed and did
not detect any solid tumor (Fig 1a, b, c). Lumbar punc-
ture was performed repeatedly, and headache could be
temporary alleviated every time. Opening pressure in-
creased from 200 to 350 mmH2O, but CSF cytology
showed no evidence of malignant cells. Her CSF carbo-
hydrate antigen (CA) 12-5, carbohydrate antigen 19-9
(CA19-9) were 976.7U/mL, 126.7U/mL compared to
1087.2U/mL and 130.9U/mL in serum. Chest and abdo-
men computed tomography (CT) scan showed no evi-
dence of abnormality. Two weeks after admission, the
patient had frequent tonic-clonic seizures, and com-
plained of severe headache. Multidisciplinary teamwork
recommended repeated CSF cytology examination, and
brain MRI scan using gadobutrol (gadolinium-DO3A-
butriol, Gadovist 1.0; Schering, Berlin, Germany) as
contrast agent. Gadobutrol is not covered by patient’s
medical insurance in our hospital and patients need to
pay for it. As a result, we chose the gadopentetate
dimeglumine which is in the range of medical insurance
as the initial contrast agent for MRI scan. Finally the
gadobutrol-enhanced MRI (Philips Achieva 3.0 T Dual
MRI, 0.1 mmol/kg, immediately after injection) de-
tected the meningeal metastasis (Fig 1d), and supported
the diagnosis of meningeal carcinomatosis. Unfortu-
nately the patient’ condition deteriorated very quickly
and died 10 days later.
Case 2
A 53-year-old female was referred to our department
from a local hospital for further diagnosis and treatment
Fig. 1 Axial magnetic resonance imaging of brain: T1-weighted imaging (a), T2-weighted imaging (b) and Gadopentetate dimeglumine-enhanced
T1-weighted image (c) do not detect any solid tumor or enhancement meninges. While the gadobutrol-enhanced T1-weighted image shows
serpentine enhancement along the surface of the brain (d)
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after being diagnosed with a space-occupying lesion in
the left occipital lobe. The patient presented with head-
ache accompanied by nausea and vomiting for 10 days.
In 2010, she had been diagnosed with and resected for
gastric adenocarcinoma. Gadopentetate dimeglumine-
enhanced MRI scan (Philips Achieva 3.0 T Dual MRI,
0.1 mmol/kg, immediately after injection) was performed
to identify the occipital lesion. On the MRI scan, an
ovoid mass with the diameter of 1.6 centimeter can be
seen in the left occipital lobe. The mass was hyperin-
tense on T1-weighted images, and iso- to hypointense
on T2-weighted images (Fig 2a, b). After administration
of meglumine gadopentetate, evident homogeneous en-
hancement was seen (Fig. 2c). The patient was diagnosed
metastatic left occipital tumor from gastric adenocarcin-
oma, and Gamma knife surgery (GKS) with the marginal
dose of 22 Gy was given. Three days after GKS, the pa-
tient had one time seizure of absences, and complained
of aggravation of the headache. A brain CT scan showed
no evidence of the tumor stroke. Considering the possi-
bility of meningeal carcinomatosis, lumbar puncture was
performed, but CSF cytology showed no evidence of ma-
lignant cells. Gadobutrol-enhanced MRI (Philips Achieva
3.0 T Dual MRI, 0.1 mmol/kg, immediately after injec-
tion) was performed, and meningeal disseminations
around the cerebellum were detected (Fig 2f ) except for
the evident homogeneous enhancement mass in the left
occipital lobe (Fig 2d). Therefore, a diagnosis of menin-
geal carcinomatosis was made. Radiotherapy and chemo-
therapy were recommended, while the patient chose
medical treatment and died 2 months later.
Conclusions
A time course chart summarizing key events of the two
cases is shown in the Fig. 3
Meningeal carcinomatosis is the last stage of patients
with malignant tumors. Basically, CSF dissemination
may happen in all patients with a malignant tumor but
is most common in patients affected by lung cancer,
breast carcinoma, melanoma or hematologic neoplasms
such as lymphoma and leukemia [4]. The two patients
both had malignant tumors, one with cervical cancer
Fig. 2 Gadopentetate dimeglumine-enhanced MRI scan shows an ovoid mass with the diameter of 1.6 centimeter in the left occipital lobe. The
mass is hyperintense on T1-weighted image (a), iso- to hypointense on T2-weighted image (b), evident homogeneous enhancement on
Gadopentetate dimeglumine-enhanced (c) and gadobutrol-enhanced (d) T1-weighted image. Gadobutrol-enhanced T1-weighted image detects
nodular enhancement around the cerebellum (f) while gadopentetate dimeglumine-enhanced T1-weighted image shows no abnormality (e)
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and another with gastric adenocarcinoma. Recent stud-
ies have suggested that the incidence of MC is higher
than previously reported owing to the increasing of pa-
tients with advanced cancer and the development of
neuroradiographic examination with gdMRI. However,
timely diagnosis of MC may be challenging even for
expert neurologists.
The clinical presentations associated with MC are
symptoms mainly due to increased intracranial pressure
such as headache, nausea and vomiting, neck pain as
well as confusion. The two patients in this study all pre-
sented progressive headache from the early stage to the
end and the opening pressure of the first patient increas-
ing from 200 to 350 mmH2O was consistent with her
headache. The headache progresses quickly and is usu-
ally insufferable in the last stage until to cerebral hernia-
tion [5]. In view of the feature, the diagnosis of MC
could keep in mind and further examination such as
CSF cytology and brain MRI should be arranged to iden-
tify the disease. Cranial nerve palsies resulting in diplo-
pia, facial paralysis can also occur. These non-specific
symptoms may be the initial signs in patients without
tumor history [6]. Therefore the diagnosis of MC some-
times becomes extremely difficult in the early stage.
Epilepsy appears to be one of the warning signals of
deterioration. In our study, both patients had seizure in
the last stage and deteriorated quickly until to death.
Brain gdMRI plays a growing role in the diagnosis
of MC especially when CSF cytology is negative [7].
Postcontrast T1-weighted image (T1WI) is the most
sensitive MRI sequence for detecting MC. The typical
appearance of MC is serpentine, nodular, or plaque-
like enhancement within the CSF and along the
surfaces of the brain, spinal cord, and nerve roots.
MRI findings are abnormal in 75–90 % patients with
cytology-positive CSF [8]. Most experts agree that
typical MRI findings in conjunction with a consistent
clinical picture fulfill the diagnostic criteria for MC.
However, most patients are diagnosed in the last
stage especially when all the other examinations have
been given. Therefore, several studies have focused on
improving the efficiency of the brain MRI, and on
introducing new potentially useful MRI subsequences
[2, 9]. Gadobutrol is a new extracellular contrast
agent which belongs to non-ionic macrocyclic gado-
linium chelate. The lower osmolality and viscosity of
gadobutrol enables the double-concentrated solution,
which contains twice the amount of Gd chelate per
volume. The T1 relaxivity of gadobutrol is approxi-
mately 14–27 % higher than that of other 0.5-mol/L
Gd chelates [10], such as gadopentetate dimeglumine.
Quantitative analysis revealed gadobutrol provided
better image quality than conventional MR contrast
agent based on the same dose and administered over
the same time interval. In this study, we present two
cases where MC was identified on gadobutrol-
enhanced MRI but not enhancing on the traditionally
gadopentetate dimeglumine-enhanced MRI. Kim et al.
Fig. 3 Time course chart of the first (a) and second case (b). Key events are summarized
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[10], also demonstrated that gadobutrol provided higher
lesion conspicuity and enhances lesion detection in brain
metastasis compared with gadopentetate dimeglumine.
These findings may be a cue to analyze the accuracy in
the diagnosis of MC, and present a choice that may facili-
tate early diagnosis. However, these findings need to be
externally validated and its clinical value has to be verified
with additional clinical studies.
The gold diagnosis standard is CSF cytology with the
specificity of about 95 % for MC [6]. However, nearly
50 % patients are cytologically negative on the first lum-
ber puncture examination. Repeat lumbar puncture can
improve the result but little benefit is obtained after
three punctures. In the study reported by Clarke et al.
[11], 65 % of patients had CSF analysis and 28 % of them
had positive finding. Considering the low positive rate,
many studies have focused on some technique which
can elevate the sensitivity of CSF examination. Subira
et al. studied the diagnostic significance of flow cytome-
try immunophenotyping (FCI) in patients with MC, and
found that FCI showed greater sensitivity and negative
predictive value (79.79 % and 68.85 respectively) [8, 12].
Emilie et al. studied the validity of CSF CA15-3 using an
automatized immune-enzymatic technology in breast
cancer-related MC and a cut-off of 3 UI/ml for CSF
CA15-3 with 80 % sensitivity and 70 % specificity was
determined [13]. The first patient in our study also
shows high level of CSF CA12-5 and CA19-9.
MC is usually fatal for patients with advanced cancer
and the median survival ranges from 4 to 6 weeks. Consid-
ering the poor prognosis early intervention may prolong
survival and relieve symptoms for patients. Radiotherapy
and chemotherapy are the main therapeutic approaches,
and the supportive care is also very important for patients.
Because the studies of MC are small clinical series, retro-
spective analyses or clinical experience, there are no clear
guidelines which treatments fits best for each patient.
Although rare, MC should be considered a possible diag-
nosis when the patient presents with progressive headache
and further examination such as CSF cytology and brain
MRI should be arranged to identify the disease. Brain
gdMRI plays a growing role in the diagnosis of MC espe-
cially when CSF cytology is negative. Gadobutrol provides
higher lesion conspicuity and enhances lesion detection in
meningeal metastasis compared with gadopentetate dime-
glumine. These findings may be a cue to analyze the accur-
acy in the diagnosis of MC, and present a choice that may
facilitate early diagnosis.
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